Symmetry Medical sells off Clamonta aerospace subsidiary
Symmetry Medical (NYSE:SMA) said today that it sold its Clamonta Ltd. aerospace subsidiary to the HLDF Corp. for roughly $1.3 million (£0.8 million), but remains committed to the aerospace machining market.
The move prompted Symmetry to cut its guidance for 2014, sending share prices down slightly on Wall Street.
Boston Scientific’s peripherals buy bad news for Cardiovascular Systems? | Medtech Wall Street news for the week of May 19, 2014
Allied Minds prepares $140M U.K. IPO to support U.S. R&D
Boston-based innovation development group Allied Minds is planning a $140 million (£83 million) initial public offering on the London Stock Exchange in support of its effort to commercialize products in the U.S.
Medtronic CEO: I’d do Ardian, CoreValve acquisitions all over again
Echo Therapeutics battles ‘dissident’ stockholder and pool-industry board nominee
Report: Deals in the medical device sector rose 200% in Q1
Acquisition activity among medical device companies surged some 200% by value and 111% by volume during the 1st quarter compared with the same period last year, with medtech firms seeking both tuck-ins and more transformative deals aimed at navigating the new healthcare landscape, according to a PricewaterhouseCoopers report.
Activist investor Oracle revives proxy war at Biolase
M&A: Medtech makers use acquisitions to fill niches
Medical device companies opted to fill in their portfolios with niche acquisitions during the 1st quarter, rather than venturing into new treatment areas or looking to diversify, according to a report by a healthcare investment bank.
CareFusion plans $1B debt offering
CareFusion (NYSE:CFN) said it plans to offer $1 billion worth of senior notes, aiming to use the proceeds to repay another, $450 million worth of senior debt that’s coming due this year.
Is Boston Scientific’s peripherals buy bad news for Cardiovascular Systems?
Boston Scientific’s (NYSE:BSX) $415 million acquisition of Bayer AG’s interventional unit is a strong move for the company, but it may bode ill for other peripheral players.